Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. Clin Genitourin Cancer 2023;21:e394-e404. [PMID: 37316414 DOI: 10.1016/j.clgc.2023.05.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2023] [Revised: 05/05/2023] [Accepted: 05/07/2023] [Indexed: 06/16/2023]

For:	Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. Clin Genitourin Cancer 2023;21:e394-e404. [PMID: 37316414 DOI: 10.1016/j.clgc.2023.05.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2023] [Revised: 05/05/2023] [Accepted: 05/07/2023] [Indexed: 06/16/2023]

Number

Cited by Other Article(s)

Klümper N, Tran NK, Zschäbitz S, Hahn O, Büttner T, Roghmann F, Bolenz C, Zengerling F, Schwab C, Nagy D, Toma M, Kristiansen G, Heers H, Ivanyi P, Niegisch G, Grunewald CM, Darr C, Farid A, Schlack K, Abbas M, Aydogdu C, Casuscelli J, Mokry T, Mayr M, Niedersüß-Beke D, Rausch S, Dietrich D, Saal J, Ellinger J, Ritter M, Alajati A, Kuppe C, Meeks J, Vera Badillo FE, Nakauma-González JA, Boormans J, Junker K, Hartmann A, Grünwald V, Hölzel M, Eckstein M. NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. J Clin Oncol 2024;42:2446-2455. [PMID: 38657187 PMCID: PMC11227306 DOI: 10.1200/jco.23.01983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 01/31/2024] [Accepted: 02/26/2024] [Indexed: 04/26/2024] Open

Abstract

PURPOSE

The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. NECTIN4 is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate NECTIN4 amplifications as a genomic biomarker to predict EV response in patients with mUC.

MATERIALS AND METHODS

We established a NECTIN4-specific fluorescence in situ hybridization (FISH) assay to assess the predictive value of NECTIN4 CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n = 108). CNVs were correlated with membranous NECTIN4 protein expression, EV treatment responses, and outcomes. We also assessed the prognostic value of NECTIN4 CNVs measured in metastatic biopsies of non-EV-treated mUC (mUC-non-EV, n = 103). Furthermore, we queried The Cancer Genome Atlas (TCGA) data sets (10,712 patients across 32 cancer types) for NECTIN4 CNVs.

RESULTS

NECTIN4 amplifications are frequent genomic events in muscle-invasive bladder cancer (TCGA bladder cancer data set: approximately 17%) and mUC (approximately 26% in our mUC cohorts). In mUC-EV, NECTIN4 amplification represents a stable genomic alteration during metastatic progression and associates with enhanced membranous NECTIN4 protein expression. Ninety-six percent (27 of 28) of patients with NECTIN4 amplifications demonstrated objective responses to EV compared with 32% (24 of 74) in the nonamplified subgroup (P < .001). In multivariable Cox analysis adjusted for age, sex, and Bellmunt risk factors, NECTIN4 amplifications led to a 92% risk reduction for death (hazard ratio, 0.08 [95% CI, 0.02 to 0.34]; P < .001). In the mUC-non-EV, NECTIN4 amplifications were not associated with outcomes. TCGA Pan-Cancer analysis demonstrated that NECTIN4 amplifications occur frequently in other cancers, for example, in 5%-10% of breast and lung cancers.

CONCLUSION

NECTIN4 amplifications are genomic predictors of EV responses and long-term survival in patients with mUC.

Collapse

Affiliation(s)

Niklas Klümper Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany BRIDGE-Consortium Germany e.V., Mannheim, Germany
Ngoc Khanh Tran Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany
Stefanie Zschäbitz Department of Medical Oncology, National Center for Tumor Disease (NCT), University Hospital, Heidelberg, Germany
Oliver Hahn Department of Urology and Pediatric Urology, Julius Maximilians University Medical Center of Würzburg, Würzburg, Germany
Thomas Büttner Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany
Florian Roghmann BRIDGE-Consortium Germany e.V., Mannheim, Germany Department of Urology, Marien Hospital, Ruhr-University Bochum, Herne, Germany
Christian Bolenz BRIDGE-Consortium Germany e.V., Mannheim, Germany Department of Urology and Pediatric Urology, University Hospital Ulm, University of Ulm, Ulm, Germany
Friedemann Zengerling BRIDGE-Consortium Germany e.V., Mannheim, Germany Department of Urology and Pediatric Urology, University Hospital Ulm, University of Ulm, Ulm, Germany
Constantin Schwab Institute of Pathology, University of Heidelberg, Heidelberg, Germany
Dora Nagy Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany Institute of Pathology, University Hospital Bonn, Bonn, Germany
Marieta Toma Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany Institute of Pathology, University Hospital Bonn, Bonn, Germany
Glen Kristiansen Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany BRIDGE-Consortium Germany e.V., Mannheim, Germany Institute of Pathology, University Hospital Bonn, Bonn, Germany
Hendrik Heers Department of Urology, University Hospital Marburg, Marburg, Germany
Philipp Ivanyi Department of Hemostaseology, Oncology and Stem Cell Transplantation, Medical University Hannover, Hannover, Germany
Günter Niegisch Department of Urology, University Hospital Düsseldorf, Düsseldorf, Germany
Camilla Marisa Grunewald Department of Urology, University Hospital Düsseldorf, Düsseldorf, Germany
Christopher Darr Department of Urology, University Hospital Essen, Essen, Germany
Arian Farid Department of Urology, University Medical Center Göttingen, Göttingen, Germany
Katrin Schlack Department of Urology, University Hospital Münster, Münster, Germany
Mahmoud Abbas Department of Pathology, University Hospital Münster, Münster, Germany
Can Aydogdu Department of Urology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany
Jozefina Casuscelli Department of Urology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany
Theresa Mokry Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany
Michael Mayr Clinic Ottakring, Institute of Pathology and Microbiology, Wien, Austria
Dora Niedersüß-Beke Department of Internal Medicine I, Wilhelminenspital, Wien, Austria
Steffen Rausch Department of Urology, Eberhard Karls University, Tübingen, Germany
Dimo Dietrich Department of Otorhinolaryngology, University Medical Center Bonn (UKB), Bonn, Germany
Jonas Saal Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Medical Center Bonn (UKB), Bonn, Germany
Jörg Ellinger Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany
Manuel Ritter Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany BRIDGE-Consortium Germany e.V., Mannheim, Germany
Abdullah Alajati Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany
Christoph Kuppe Institute of Experimental Medicine and Systems Biology and Division of Nephrology, RWTH Aachen University, Aachen, Germany
Joshua Meeks Department of Urology, Feinberg School of Medicine, Chicago, IL
Francisco E. Vera Badillo Department of Medical Oncology, Queen's University, Kingston, Ontario, Canada
J. Alberto Nakauma-González Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands
Joost Boormans Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands
Kerstin Junker Department of Urology and Pediatric Urology, Saarland University, Homburg, Germany
Arndt Hartmann BRIDGE-Consortium Germany e.V., Mannheim, Germany Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany
Viktor Grünwald Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, Essen University Hospital, Essen, Germany
Michael Hölzel Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany
Markus Eckstein BRIDGE-Consortium Germany e.V., Mannheim, Germany Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany

Collapse

Morikawa T, Naiki T, Sugiyama Y, Naiki-Ito A, Nagai T, Etani T, Iida K, Isobe T, Noda Y, Shimizu N, Aoki M, Gonda M, Banno R, Kubota H, Ando R, Umemoto Y, Kawai N, Yasui T. C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study. Cancers (Basel) 2024;16:1725. [PMID: 38730675 PMCID: PMC11083374 DOI: 10.3390/cancers16091725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2024] [Revised: 04/24/2024] [Accepted: 04/26/2024] [Indexed: 05/13/2024] Open

Affiliation(s)

Toshiharu Morikawa Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Taku Naiki Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.) Department of Urology, Nagoya City University West Medical Center, Nagoya 467-8601, Japan
Yosuke Sugiyama Department of Pharmacy, Nagoya City University Hospital, Nagoya 467-8601, Japan;
Aya Naiki-Ito Department of Experimental Pathology and Tumor Biology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan;
Takashi Nagai Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Toshiki Etani Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Keitaro Iida Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Teruki Isobe Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Yusuke Noda Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.) Department of Urology, Anjo Kosei Hospital, Anjo 446-8602, Japan
Nobuhiko Shimizu Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Maria Aoki Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.) Department of Urology, Nagoya City University West Medical Center, Nagoya 467-8601, Japan
Masakazu Gonda Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Rika Banno Department of Urology, Konan Hospital, Konan 483-8704, Japan;
Hiroki Kubota Department of Urology, Kainan Hospital, Yatomi 498-8502, Japan;
Ryosuke Ando Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Yukihiro Umemoto Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.) Department of Urology, Nagoya City University West Medical Center, Nagoya 467-8601, Japan
Noriyasu Kawai Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)
Takahiro Yasui Department of Nephro-Urology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan; (T.M.); (T.N.); (T.E.); (K.I.); (T.I.); (Y.N.); (N.S.); (M.A.); (M.G.); (R.A.); (Y.U.); (N.K.); (T.Y.)

Collapse

Nathan P, Rajeh A, Noor M, Boldt G, Fernandes R. Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data. Curr Oncol 2024;31:2316-2327. [PMID: 38668075 PMCID: PMC11049516 DOI: 10.3390/curroncol31040172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2024] [Revised: 04/14/2024] [Accepted: 04/14/2024] [Indexed: 04/28/2024] Open

Berg SA, McGregor BA. One Size Fits Some: Approaching Rare Malignancies of the Urinary Tract. Curr Treat Options Oncol 2024;25:206-219. [PMID: 38315403 DOI: 10.1007/s11864-024-01187-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/17/2024] [Indexed: 02/07/2024]